Construction and expression of an antimicrobial peptide scolopin 1 from the centipede venoms of Scolopendra subspinipes mutilans in Escherichia coli using SUMO fusion partner

2013 ◽  
Vol 92 (2) ◽  
pp. 230-234 ◽  
Author(s):  
Huanhuan Hou ◽  
Weili Yan ◽  
Kexing Du ◽  
Yangjing Ye ◽  
Qianqian Cao ◽  
...  
2013 ◽  
Vol 92 (2) ◽  
pp. 135-140 ◽  
Author(s):  
Qi Wang ◽  
Jiaojiao Zhao ◽  
Yan Wang ◽  
Honglou Sun ◽  
Yi Jiang ◽  
...  

2010 ◽  
Vol 29 (5) ◽  
pp. 314-319 ◽  
Author(s):  
Jian Feng Li ◽  
Jie Zhang ◽  
Zhen Zhang ◽  
Hong Wei Ma ◽  
Jia Xin Zhang ◽  
...  

2009 ◽  
Vol 84 (2) ◽  
pp. 383-388 ◽  
Author(s):  
Jian Feng Li ◽  
Jie Zhang ◽  
Ren Song ◽  
Jia Xin Zhang ◽  
Yang Shen ◽  
...  

2012 ◽  
Vol 29 (2) ◽  
pp. 319-325 ◽  
Author(s):  
Fenfen Zhu ◽  
Qi Wang ◽  
Hefang Pu ◽  
Shasha Gu ◽  
Lan Luo ◽  
...  

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Kaitlin S. Witherell ◽  
Jason Price ◽  
Ashok D. Bandaranayake ◽  
James Olson ◽  
Douglas R. Call

AbstractMultidrug-resistant bacteria are a growing global concern, and with increasingly prevalent resistance to last line antibiotics such as colistin, it is imperative that alternative treatment options are identified. Herein we investigated the mechanism of action of a novel antimicrobial peptide (CDP-B11) and its effectiveness against multidrug-resistant bacteria including Escherichia coli #0346, which harbors multiple antibiotic-resistance genes, including mobilized colistin resistance gene (mcr-1). Bacterial membrane potential and membrane integrity assays, measured by flow cytometry, were used to test membrane disruption. Bacterial growth inhibition assays and time to kill assays measured the effectiveness of CDP-B11 alone and in combination with colistin against E. coli #0346 and other bacteria. Hemolysis assays were used to quantify the hemolytic effects of CDP-B11 alone and in combination with colistin. Findings show CDP-B11 disrupts the outer membrane of E. coli #0346. CDP-B11 with colistin inhibits the growth of E. coli #0346 at ≥ 10× lower colistin concentrations compared to colistin alone in Mueller–Hinton media and M9 media. Growth is significantly inhibited in other clinically relevant strains, such as Acinetobacter baumannii, Pseudomonas aeruginosa, and Klebsiella pneumoniae. In rich media and minimal media, the drug combination kills bacteria at a lower colistin concentration (1.25 μg/mL) compared to colistin alone (2.5 μg/mL). In minimal media, the combination is bactericidal with killing accelerated by up to 2 h compared to colistin alone. Importantly, no significant red blood hemolysis is evident for CDP-B11 alone or in combination with colistin. The characteristics of CDP-B11 presented here indicate that it can be used as a potential monotherapy or as combination therapy with colistin for the treatment of multidrug-resistant infections, including colistin-resistant infections.


Sign in / Sign up

Export Citation Format

Share Document